Extractive Spectrophotometric for Determination of Dihydroergocryptine Mesylate in Pharmaceutical Preparations

MALEK OKDEH^{1,*}, AMIR ALHAJ SAKUR² and BANANA ALFARES¹

¹Department of Chemistry, Faculty of Science, Teshreen University, Lattakia, Syria

²Department of Analytical and Food Chemistry, Faculty of Pharmacy, Aleppo University, Aleppo, Syria

*Corresponding author: E-mail: dr.malekokdeh@yahoo.com

Received: 24 May 2013;

Accepted: 20 January 2014;

Published online: 10 May 2014;

AJC-15134

Simple, accurate and highly sensitive spectrophotometric method has been developed for the rapid determination of dihydroergocryptine mesylate in pure form and pharmaceutical formulations. The spectrophotometric method was based on the formation of binary complex (ion-pair complex) between the dihydroergocryptine mesylate and chromotrope 2R in acidic buffer, giving purple color. The absorbance of dichloromethane extracted complex was measured at 531 nm. The effects of analytical parameters on the reported systems were investigated. The complexation reaction was extremely rapid at room temperature and the absorption value remains unchanged up to 24 h. Beer's law was obeyed in the concentration ranges of 3-180 µg/mL, detection limit was 0.08 µg/mL and the molar absorptivity coefficient were $6.8 \times 10^3 \text{ L mol}^{-1} \text{ cm}^{-1}$ for chromotrope 2R. Recoveries were between 97.20-101.11 %. Interferences of the other ingredients and excipients were not observed.

Keywords: Extractive spectrophotometry, Complex formation, Dihydroergocryptine mesylate, Chromotrope 2R.

INTRODUCTION

Dihydroergocryptine mesylate, (2R,4R,7R)-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-(propan-2-yl)-3-oxa-6,9-diazatricyclo[7.3.0.0^{2,6}]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraene-4-carboxamide, molecular weight 673.8 g mol⁻¹ (Fig. 1). It belongs to the pharmaco-therapeutic group peripheral vasodilator (C: cardiovascular system), there is dihydroergocryptine mesylate with caffeine and this drug indicated in age related minor neurological disorders in reynaud, syndrome (circulatory disorders of the extremities)¹.

Fig. 1. Chemical structure of dihydroergocryptine mesylate

Few methods have been described for the determination of dihydroergocryptine mesylate, in human plasma and urine samples using on-line sample extraction-column-switching

reversed-phase liquid chromatography-mass spectrometry², separation and determination of four ergot alkaloids, dihydro-ergotameme-, dihydroergocornine-, dihydroergocryptine- and dihydroergocristine methanesulfonates by high performance liquid chromatography³. The United State Pharmacopoeia and British Pharmacopoeia do not indicate an official method for the quantification of dihydroergocryptine mesylate and no extractive spectrophotometric methods for the determination of dihydroergocryptine mesylate have been reported in pharmaceutical preparation yet.

Many materials have been determined by using chromotrope 2R *e.g.*, spectrophotometric determination meclozine HCl and papaverine HCl in their pharmaceutical formulations⁴, sildenafil citrate in pure form and in pharmaceutical formulation⁵ and many extractive spectrophotometric methods for the determination active material in pharmaceutical preparations for example doxepin hydrochloride⁶, nifedipine⁷, phenothiazine derivatives⁸, fluoxetine and fluvoxamine⁹, fluoroquinolone derivatives¹⁰, ceterizine HCl¹¹, sildenafil citrate (Viagra)¹², sulphonamide drugs in pure and pharmaceutical preparations through ion-pair¹³, anti-Parkinsonian drug¹⁴, cyclizine¹⁵, disopyramide and irbesartan¹⁶, trifluoperazine hydrochloride¹⁷ and levofloxacin¹⁸.

In the present work, new simple and sensitive analytical method was developed for the determination of dihydro-

ergocryptine mesylate. The method was applied for the analysis of international and local pharmaceutical products samples.

EXPERIMENTAL

Measurements were made on a Jasco V-650 model spectrophotometer UV-Visible (Japan Spectroscopic Co. Ltd., Tokyo) with a scanning speed of 400 nm/min and a bandwidth of 2 nm, equipped with 10 mm matched quartz cells. All absorption spectra were made for electronic spectral measurements between (190–1100 nm). The pH measurements were made with CRISON pH meter Model GLP21 made in EU.

Stock standard solution of dihydroergocryptine mesylate (1×10^{-3} M) was prepared by dissolving 67.8 mg (considering the purity) of drug in double distilled water and diluted to the mark in 100 mL volumetric flask. The standard solution was prepared by dilution of the stock standard solution with double distilled water to reach concentration (1×10^{-4} M) of dihydroergocryptine mesylate. This solution was stored in well-closed vessel, the solution is stable. Solutions of reagent Chromotrope 2R were prepared with a concentration of (1×10^{-3} M) by dissolving suitable weight of the reagent in double distilled water and diluted to the mark in 100 mL volumetric flasks separately.

The aqueous solution of chromotrope 2R dye was stable for several months. Spectroscopic grade dichloromethane was used for extraction from SCP (Surchem product Ltd, England).

Procedure for the assay of bulk sample: Aliquots of the standard dihydroergocryptine mesylate solutions were transferred into a series of 50 mL separating funnels, 3 mL of Britton buffer and 3.5 mL of reagent chromotrope 2R were added and mixed well, a 10 mL amount of dichloromethane was added with three portions and the mixture was shaken well. The formed ion associates were extracted with 3 mL by shaking for 5 min, then repeating the extraction step twice by using new 3 mL aliquots of the extractant for every extraction. The reaction mixture was allowed to separate into two phases. The organic layer was collected into 10 mL calibrated measuring flask and the volume was made up to the mark with the extractant solvent. The absorbance of the separated dichloromethane layer was measured at a maximum 531 nm, for the complex chromotrope 2R-dihydroergocryptine mesylate, against the reagent blank. The standard calibration plot was prepared to calculate the amount of the analyzed drug in bulk samples. All measurements were carried out at room temperature (25 ± 2 °C).

Procedure for formulations: The contents of 20 tablets of dihydroergocryptine mesylate drugs were weighed, powdered and an accurately weighed portion equivalent to 4 mg of the drug was dissolved in double distilled water, shaken in mechanical shaker for 5 min and then filtered. The filtrate was made up to 100 mL volumetric flask. The suitable aliquot was analyzed using the procedure described earlier.

RESULTS AND DISCUSSION

Preliminary investigations have been shown that dihydroergocryptine mesylate reacts with chromotrope 2R in Britton buffer to give dichloromethane-soluble ion-association complexes. The optimum reaction conditions for quantitative

determination of the ion pair complex was established *via* a number of preliminary experiments.

Several parameters such as acidity, type and amount of acid added, reagent concentration, sequence of addition and effect of extracting solvent were optimized to achieve high sensitivity, low blank reading and reproducible results.

Effect of extracting solvent: Several organic solvents (ethyl ether, chloroform, dichloromethane, ethyl acetate, carbon tetra chloride) were examined for their ability to extract dihydroergocryptine mesylate-dye ion-pair complexes. The dichloromethane was found to be the most suitable solvent for quantitative extraction of the complex.

Effect of time and temperature: The effect of time on the formation and stability of the ion-associates was studied by measuring the absorbencies of the extracted ion-associates at increasing time intervals, the results show that the ion-associates were formed almost instantaneously in the cases at room temperature (25 ± 2 °C). The color of the dihydroergocryptine mesylate-chromotrope 2R remained stable for 8–10 h. after these intervals, a slight decrease in color intensity occurred.

Effect of acidity: The effect of pH was studied by extracting the colored complex in the presence of various buffers such as Britton, acetate, borate and acid media. It was observed that the maximum color intensity and constant absorbance were found in Britton buffer of pH 1.8 for dihydroergocryptine mesylate-chromotrope 2R system using 3 mL of buffer as shown in Fig. 2.

Fig. 2. Effect of the pH value on absorption of dihydroergocryptine mesylate-dye complex

Effect of amount of Britton buffer: The optimum amount of Britton buffer for the assay of drugs was studied. 3 mL of Britton buffer pH 1.8 was sufficient for complete color development for dihydroergocryptine mesylate-dye complex (Fig. 3).

Molar ratio determination of dihydroergocryptine mesylate-dye complexes: The molar ratio of the drug to dye of the colored complex was determined using the molar ratio¹⁹ and continuous variation²⁰ methods. The ratio were found to be 1:2 for dihydroergocryptine mesylate:chromotrope 2R (Figs. 4 and 5).

Fig. 3. Effect of the buffer volume (pH = 1.8) on absorption of dihydroergocryptine mesylate-dye complex

Fig. 4. Continuous Variations plots for dihydroergocryptine mesylate-dye

Linearity and range: Beer's law limits, molar absorptivity, linear regression equation, correlation coefficient and detection limit determined for method is given in Table-1. A linear relationship was found between the absorbance at $\lambda_{\max}$ and the concentration of the drug in the ranges 3-180 $\mu\text{g/mL}$ for chromotrope 2R.

Fig. 5. Molar ratio plots for dihydroergocryptine mesylate-dye

TABLE-1
SPECTRAL CHARACTERISTICS OF DIHYDROERGOCRYPTINE MESYLATE-DYE COMPLEXES

Parameters	Extraction method with dihydroergocryptine mesylate-chromotrope 2R
Buffer pH	1.8
$\lambda_{\max}$ (nm)	531
Stoichiometric relationship	1:2
Beer's law limit ($\mu\text{g mL}^{-1}$)	3.0-180.0
Molar absorptivity ($\text{L mol}^{-1} \text{cm}^{-1}$)	6.9×10^3
Linear regression equation	$A = 0.0100C + 0.0033$
Correlation coefficient, r	0.9999
LOD ($\mu\text{g mL}^{-1}$)	0.23
LOQ ($\mu\text{g mL}^{-1}$)	0.75
Range of error	$\pm 1.32 \%$

The graph shows negligible intercept and is described by the regression equation, $A = mC + b$ (where A is the absorbance of 1 cm layer, m is the slope, b is the intercept and C is the concentration of the measured solution in $\mu\text{g mL}^{-1}$) obtained by the least-squares method²¹. The high molar absorptivity of the resulting colored complexes indicate the good sensitivity of the method (Fig. 6).

Fig. 6. Calibration plot of dihydroergocryptine mesylate using chromotrope 2R

Accuracy and precision: The results obtained are summarized in Table-2. The low values of relative standard deviation (RSD) indicate good precision and reproducibility of the method. The average percent recoveries obtained were 97.20-101.11 % for chromotrope 2R, indicating good accuracy of the methods.

Application to pharmaceutical dosage forms: The proposed method have been successfully applied to the determination of dihydroergocryptine mesylate in pharmaceutical preparations Table-3. The ingredients in the tablets did not interfere in the experiments.

Conclusion

The proposed method for the estimation of dihydroergocryptine mesylate using chromotrope 2R is better than many reported methods. The method is rapid, simple and have good sensitivity and accuracy. Proposed method makes use of simple reagent, which an ordinary analytical laboratory can afford. The high recovery percentage and low relative standard deviation reflect the high accuracy and precision of the proposed method. The method is easy, applicable to a wide

TABLE-3
ESTIMATION OF DIHYDROERGOCRYPTINE MESYLATE IN (DHECM) TABLETS AND ORAL SOLUTION

ESTIMATION OF DIHYDROERGOCRYPTINE MESYLATE IN (SRJIA) TABLETS AND ORAL SOLUTION							
Formulation (Tablets)	Dihydroergocryptine mesylate (mg/tab)	Chromotrope 2R					
		(µg/mL)			Content determined (mg/tab)	RSD (%)	R* (%)
Taken	Found*	SD					
VASOBRAL*	4	80	81.70	1.14	4.09	1.40	102.12
		120	122.60	0.72	4.09	0.59	102.17
		160	166.25	0.91	4.16	0.55	103.91
Mean R*% ± RSD %				102.73 ± 1.15			
VASOBRAL**	4	80	81.09	0.37	4.05	0.46	101.37
		120	121.84	0.73	4.06	0.60	101.53
		160	162.43	0.51	4.06	0.31	101.52
Mean R* % ± RSD %				101.47 ± 0.66			
Average of five determinations. R means Recoverv. VASOBRAL* from K.C Pharma (Srjia). VASOBRAL** from Chiesi (Italy)							

Average of five determinations. R means Recovery. VASOBRAI* from K.C Pharma (Syria). VASOBRAI** from Chiesi (Italy)

TABLE 2
EVALUATION OF PRECISION AND ACCURACY OF
THE PROPOSED METHODS FOR DETERMINATION OF
DIHYDROERGOCRYPTINE MESILATE IN PURE FORM

Dye	Dihydroergocryptine mesilate, µg mL ⁻¹			RSD (%)	Recovery (%)	Confidence limit
	Taken	Found*	SD			
Chromotrope 2R	3.00	2.92	0.04	1.32	97.20	2.92±0.05
	6.00	5.84	0.10	1.68	97.40	5.84±0.12
	8.00	7.82	0.04	0.48	97.80	7.82±0.05
	10.00	9.76	0.10	1.05	97.62	9.76±0.13
	20.00	19.58	0.20	2.73	97.92	19.58±0.25
	40.00	39.90	1.32	3.30	99.75	39.90±1.64
	60.00	60.66	1.35	2.22	101.11	60.66±1.67
	80.00	81.39	0.98	1.21	101.74	81.39±1.22
	100.00	101.08	0.99	0.98	101.08	101.08±1.23
	120.00	120.46	0.54	0.45	100.38	120.46±0.67
	160.00	161.34	0.79	0.49	100.84	161.34±0.98
	180.00	179.05	0.92	0.51	99.47	179.05±1.14

*Average of five determinations

range of concentration, besides being less time consuming and depend on simple reagent which is available, thus offering economic and acceptable methods for the routine determination of dihydroergocryptine mesylate in its formulations.

REFERENCES

- L. Battistin, P.G. Bardin, F. Ferro-Milone, C. Ravenna, V. Toso and G. Reboldi, *Acta Neurol. Scand.*, **99**, 36 (1999).
- G. Friedrich, K. Appel, T. Rose, M. Wangemann, M. Althaus and K. Rissler, *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.*, **808**, 131 (2004).
- S.L. Ali and T. Strittmatter, *J. Pharmaceut.*, **4**, 111 (1979).
- N.T. Abdel-Ghani and A.F. Shoukry and Y.M. Issa and O.A. Wahdan, *J. Pharm. Biomed. Anal.*, **28**, 373 (2002).
- Y.M. Issa, W.F. El-Hawary, A.F.A. Youssef and A.R. Senosy, *Spectrochim. Acta A*, **75**, 1297 (2010).
- W. Misiuk, *IL Farmaco*, **60**, 61 (2005).
- A. Moretto, L. Tesolin, F. Marsilio, M. Schiavon, M. Berna and F.M. Veronese, *IL Farmaco*, **59**, 1 (2004).
- K. Basavaiah and G. Krishnamurthy, *Talanta*, **46**, 665 (1998).
- B. Starczewska and K. Mielech, *J. Pharm. Biomed. Anal.*, **23**, 243 (2000).
- C.S.P. Sastry, K.R. Rao and D.S. Prasad, *Talanta*, **42**, 3 (1995).
- B.G. Gowda, M.B. Melwanki and J. Seetharamappa, *J. Pharm. Biomed. Anal.*, **25**, 1021 (2001).
- N.D. Dinesh, P. Nagaraja, N.M.M. Gowda and K.S. Rangappa, *Talanta*, **57**, 757 (2002).
- F. El-Baz, *J. Adv. Res.*, **1**, 3 (2010).
- M. Iqbal, Z. Khatri, A. Ahmed, J. Mughal and K. Ahmed, *J. Saud. Chem. Soc.*, **16**, 1 (2012).
- A.-S.H. Nora, *Saudi Pharm. J.*, **20**, 3 (2012).
- H.E. Abdellatif, *Spectrochim. Acta A*, **66**, 1248 (2007).
- M.E.M. Hassouna, A.M. Adawi and E.A. Al, *Egypt. J. Forensic Sci.*, **2**, 62 (2012).
- S. Ashour and R. Al-Khalil, *IL Farmaco*, **60**, 771 (2005).
- J.H. Yoe and A.L. Jones, *Ind. Eng. Chem. (Anal. Ed.)*, **16**, 111 (1944).
- C.W. Vosburgh and R.G. Cooper, *J. Am. Chem. Soc.*, **63**, 437 (1941).
- J.C. Miller and J.N. Miller, *Statistics for Analytical Chemistry*, Ellis Horwood, Chichester, edn. 3, pp. 119-130 (1993).